FTC Warns PBM Practices Are Driving Higher Drug Costs and Employers Start to Push Back

RegulatoryNegative

AI Analysis

Summary

The FTC has warned that PBM practices are contributing to rising drug costs, prompting employers to challenge the industry amid increased regulatory scrutiny and litigation. US-Rx Care CEO argues employers cannot wait for government intervention to address the issue.

Outcome Details

FTC warns PBM practices are driving higher drug costs; increased regulatory scrutiny and litigation against PBM industry

Importance:6/10

Sentiment:

-0.70

PBMRegulatoryDrug CostsFTCEmployer PushbackLitigation

Read the original article

Published by PR Newswire Pharma on March 2, 2026 1:13 PM

Read Original